Enliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Check

Related Articles

Costco's Unyielding Valuation Faces a Margin Reality Check

4 months ago

Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions

3 months ago

The Olaf Incident: A Chilling Reality Check for AI

7 months ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

4 months ago

Category

You may also like

Stock News•3 weeks ago

Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock

Eli Lilly's largest shareholder filed to sell ~$347M of stock, even as analysts keep raising price targets. The opposing signals leave investors weighing insider supply against bullish Street revision...

LLY

Share

Stock News•4 weeks ago

Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling

Enliven Therapeutics (NASDAQ:ELVN) shares fell 4.5% to $43.44 on Tuesday after insider selling activity, with volume of 62,397 shares, 95% below the 1.25M average.

ELVN

Share

Stock News•2 months ago

After Climbing 157% in Five Years, Insider Dumps Shares of Regional Bank

A regional bank insider sold 17% of direct holdings at $53 per share, trimming equity interest after shares climbed 157% in five years. The stock now trades near the transaction price, signaling poten...

OFG

Share